Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs

NEXT STORY
Akoya Biosciences Appoints Pascal Bamford, PhD, as SVP, R&D and Laboratory Operations
PREV STORY
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs

NEXT STORY
Akoya Biosciences Appoints Pascal Bamford, PhD, as SVP, R&D and Laboratory Operations
PREV STORY
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares

author_avatar
NASDAQ Market News

BioSig PURE EP System Featured in the Editorial of EP Lab Digest

author_avatar
NASDAQ Market News

Viral Inactivation Market is Projected to Surpass US$5.736 bn by 2025, Says TMR

Global Viral Inactivation Market to Accumulate Revenues Worth US$5.736 bn by 2025 as New ...

author_avatar
NASDAQ Market News